SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
EGAN E MICHAEL

(Last) (First) (Middle)
BLDG 96
13TH ST

(Street)
CHARLESTOWN MA 02129

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DIACRIN INC /DE/ [ DCRN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2003
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2003 D 66,664 D $0 ( 1 ) $0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $10.75 08/21/2003 D 20,000 ( 2 ) 12/17/2007 Common Stock 20,000 ( 2 ) 0 D
Employee stock option (right to buy) $5.25 08/21/2003 D 20,000 ( 3 ) 12/21/2008 Common Stock 20,000 ( 3 ) 0 D
Employee stock option (right to buy) $6.25 08/21/2003 D 20,000 ( 4 ) 12/30/2009 Common Stock 20,000 ( 4 ) 0 D
Employee stock option (right to buy) $4.688 08/21/2003 D 20,000 ( 5 ) 12/27/2010 Common Stock 20,000 ( 5 ) 0 D
Employee stock option (right to buy) $2.08 08/21/2003 D 40,000 ( 6 ) 01/14/2012 Common Stock 40,000 ( 6 ) 0 D
Employee stock option (right to buy) $1.06 08/21/2003 D 20,000 ( 7 ) 01/13/2013 Common Stock 20,000 ( 7 ) 0 D
Employee stock option (right to buy) $1.25 08/21/2003 D 15,000 ( 8 ) 12/19/2004 Common Stock 15,000 ( 8 ) 0 D
Employee stock option (right to buy) $2.5 08/21/2003 D 5,000 ( 9 ) 12/02/2003 Common Stock 5,000 ( 9 ) 0 D
Employee stock option (right to buy) $1.4 08/21/2003 D 30,000 ( 10 ) 06/14/2005 Common Stock 30,000 ( 10 ) 0 D
Employee stock option (right to buy) $8.25 08/21/2003 D 20,000 ( 11 ) 11/18/2006 Common Stock 20,000 ( 11 ) 0 D
Explanation of Responses:
1. Disposed of pursuant to a merger agreement between the issuer and GenVec, Inc. in exchange for 101,942 shares of GenVec common stock having an aggregate value of $235,486 on the effective date of the merger.
2. These stock options, which provide for vesting in four equal annual installments beginning on December 17, 1998, were assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $7.03 per share.
3. These stock options, which provide for vesting in four equal annual installments beginning on December 21, 1999, were assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $3.44 per share.
4. These stock options, which provide for vesting in four equal annual installments beginning on December 30, 2000, were assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $4.09 per share.
5. These stock options, which provide for vesting in four equal annual installments beginning on December 27, 2001, were assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $3.07 per share.
6. This stock option, which provides for vesting in four equal annual installments beginning on January 14, 2003, was assumed by GenVec in connection with the merger and replaced with an option to purchase 61,168 shares of GenVec common stock at an exercise price of $1.36 per share.
7. This stock option, which provides for vesting in four equal annual installments beginning on January 13, 2004, was assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $0.70 per share.
8. This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger an replaced with an option to purchase 22,938 shares of GenVec common stock at an exercise price of $0.82 per share.
9. This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 7,646 share of GenVec common stock at an exercise price of $1.64 per share.
10. This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 45,876 shares of GenVec common stock at an exercise price of $0.92 per share
11. This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $5.40 per share.
/s/ E. Michael Egan 08/21/2003
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.